First, to assess the potential of GPX4 and FSP1 as therapeutic targets, cell death rates of lung adenocarcinoma cells treated with GPX4 inhibitors (RSL3 and ML210) and FSP1 inhibitor (iFSP1) alone or in combination were determined. This evidence concerns the gene AIFM2 and lung adenocarcinoma.